jwh-198 jwh-198 jwh-198 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. it was invented by the pharmaceutical company sanofi-winthrop in the early 1990s. jwh-198 has a binding affinity at the cb1 receptor of 10 nm, binding around four times more tightly than the parent compound jwh-200, which has no substitution on the naphthoyl ring. it has been used mainly in molecular modelling of the cannabinoid receptors. jwh-198legal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: class b us: schedule i identifiers iupac name (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone cas number166599-76-4 npubchem cid10319620chemspider8495084 nuniij53igm38pbcomptox dashboard (epa)dtxsid40168133 chemical and physical dataformulac26h26n2o3molar mass414.505 g·mol−13d model (jsmol)interactive image smiles c4coccn4ccn2cc(c5ccccc25)c(=o)c3c1ccccc1c(oc)cc3 inchi inchi=1s/c26h26n2o3/c1-30-25-11-10-22(19-6-2-3-8-21(19)25)26(29)23-18-28(24-9-5-4-7-20(23)24)13-12-27-14-16-31-17-15-27/h2-11,18h,12-17h2,1h3 nkey:qwhsuxwddkwtog-uhfffaoysa-n n ny (what is this?) (verify) in the united states, all cb1 receptor agonists of the 3-(1-naphthoyl)indole class such as jwh-198 are schedule i controlled substances.